Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 Oct 24;95(11):1474–1482. doi: 10.1038/sj.bjc.6603437

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2006 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

(A) Survival (Kaplan–Meier plot) of the evaluable patients treated with different doses of GV1001. Median survival (95% conf. int.): Low-dose group (n=8); 119 days (31–190), intermediate dose group (n=16); 260 days (133–337), and high-dose group (n=14); 153 days (106–249). Intermediate vs low dose; P=0.006, intermediate vs high dose; P=0.05 (log-rank). (B) Survival (Kaplan–Meier plot) of all immune responders (n=24) vs all non-responders (n=14) in the whole evaluable study population. Median survival (95% confidene interval) was; 216 days (146–323) for the immune responders and 88 days (53–190) for the non-responders. P=0.0001 (log-rank).